Acquisition of Surgical Biologics, LLC (Details) (USD $)	3 Months Ended		9 Months Ended			9 Months Ended				9 Months Ended			9 Months Ended									0 Months Ended	1 Months Ended		9 Months Ended						9 Months Ended		9 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Jan. 05, 2011	Sep. 30, 2012 Trade names and trademarks [Member]		Jan. 05, 2011 Trade names and trademarks [Member]	Jan. 05, 2011 In-process research and development - liquid [Member]	Sep. 30, 2012 In-process research and development - other [Member]		Jan. 05, 2011 In-process research and development - other [Member]	Sep. 30, 2012 Customer Relationships [Member]		Sep. 30, 2012 Supplier Relationships [Member]		Sep. 30, 2012 Patents and know-how [Member]		Sep. 30, 2012 Licenses and permits [Member]		Jan. 05, 2011 Licenses and permits [Member]	Jan. 05, 2011 Surgical Biologics [Member]	Jul. 31, 2012 Surgical Biologics [Member]	Apr. 30, 2012 Surgical Biologics [Member]	Sep. 30, 2012 Surgical Biologics [Member]	Sep. 30, 2012 Surgical Biologics [Member] Trade names and trademarks [Member]	Sep. 30, 2012 Surgical Biologics [Member] In-process research and development - liquid [Member]	Sep. 30, 2012 Surgical Biologics [Member] In-process research and development - other [Member]	Sep. 30, 2012 Surgical Biologics [Member] Customer Relationships [Member]	Jan. 05, 2011 Surgical Biologics [Member] Customer Relationships [Member]	Sep. 30, 2012 Surgical Biologics [Member] Supplier Relationships [Member]	Jan. 05, 2011 Surgical Biologics [Member] Supplier Relationships [Member]	Sep. 30, 2012 Surgical Biologics [Member] Patents and know-how [Member]	Jan. 05, 2011 Surgical Biologics [Member] Patents and know-how [Member]	Sep. 30, 2012 Surgical Biologics [Member] Licenses and permits [Member]
Business Acquisition [Line Items]
Cash Paid																						$ 500,000
Convertible Promissory Notes, number of shares issuable (in shares)																						1,250,000
Convertible Promissory Notes, interest rate (in hundredths)																						4.00%
Common Stock issued (in shares)			893,267																			5,250,000	893,267	2,632,576
Common Stock valued	893,267		893,267																			7,087,500
Common stock held in escrow (in shares)																						525,000
Contingent Liability for Accrued Earn-Out Acquisition Consideration [Roll Forward]
Beginning balance																									7,410,503
Common stock issued on earn-out			(3,185,223)																						(3,185,223)
(Gains) or losses included in earnings	1,320,000	0	1,320,000	0																					1,320,000
Ending balance																						(7,404,700)			5,545,280
Number of Consecutive Trading Days																									20 days
Convertible Promissory Note, conversion price (in dollars per share)																									$ 1
Convertible Promissory Note, stock price trigger (in dollars per share)																									$ 1.75
Repayments of Convertible Debt			427,126	0																			177,000
Actual purchase price allocated [Abstract]
Value of 5,250,000 shares issued at $1.35 per share																						7,087,500
Cash paid at closing																						350,000
Cash retained for working capital																						150,000
Assumed Debt																						182,777
Convertible Secured Promissory Note																						1,250,000
Fair value of earn-out																						7,404,700			(5,545,280)
Total fair value of purchase price																						16,424,977
Common Stock, share price (in dollars per share)					$ 1.35
Tangible assets:
Debt-free working capital					671,880																	671,880
Other assets, net																						385
Property, plant and equipment																						72,866
Tangible assets purchased																						745,131
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets																					13,000									3,520,000		241,000		5,530,000
Weighted average useful life													14 years	[1]	14 years	[1]	14 years	[1]	3 years	[1]									14 years		14 years		14 years		3 years
Acquired Indefinite-lived Intangible Assets [Line Items]
Acquired intangible asset								1,008,000	2,160,000			25,000
Weighted average useful life						indefinite	[1]			indefinite	[1]															indefinite	indefinite	indefinite
Total acquired intangible assets					12,497,000
Goodwill					3,182,846
Working capital [Abstract]
Cash					33,583
Prepaid Expenses					2,738
Accounts Receivable					181,087
License Receivable					340,000
Inventory					347,106
Accounts payable and accrued expenses					(196,101)
Deferred rent and customer deposits					(36,533)
Debt-free working capital					671,880																	671,880
Current portion of debt					(62,590)
Long-term debt					(21,187)
Line of credit					(99,000)
Net working capital					489,103
Deposits					16,582
Deferred rent (non-current)					$ (16,197)

[1] On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for customer and supplier relationships, patents and know-how, licenses/permits, trade names and trademarks and in-process research and development.